Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology
Volume 24, Issue 6, Pages 380-384
Original Article

Ankaferd Blood Stopper for Controlling Gastrointestinal Bleeding due to Distinct Benign Lesions Refractory to Conventional Antihemorrhagic Measures

Mevlut Kurt,1 Ibrahim Koral Onal,1 Meral Akdogan,1 Murat Kekilli,1 Mehmet Arhan,1 Abdurrahim Sayilir,1 Erkin Oztas,1 and Ibrahim Celalettin Haznedaroglu2

1Department of Gastroenterology, Turkiye Yuksek Ihtisas Teaching and Research Hospital, Turkey
2Department of Hematology, Hacettepe University Medical Faculty, Ankara, Turkey

Received 26 August 2009; Accepted 25 October 2009

Copyright © 2010 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


OBJECTIVE: To assess the hemostatic efficacy of the Ankaferd Blood Stopper (ABS, Ankaferd Health Products Ltd, Turkey) hemostatic agent for controlling gastrointestinal bleeding associated with various benign lesions refractory to conventional antihemorrhagic measures.

METHODS: The records of all patients who underwent upper and lower endoscopy procedures at the Turkiye Yuksek Ihtisas Teaching and Research Hospital (Ankara, Turkey) between April 2008 and June 2009 were reviewed. Patients in whom ABS was used as a primary or adjuvant hemostatic agent were included in the study. Rates of bleeding control and postprocedural complications were documented.

RESULTS: Hemostasis with no immediate complications was achieved in all patients within seconds of endoscopic application of ABS.

CONCLUSIONS: ABS may have a role as a primary treatment or as an adjuvant to conventional modalities used to control gastrointestinal bleeding. Prospective controlled studies are needed to help establish its efficacy and, perhaps, offer a comparison with conventional hemostatic interventions.